Progesterone and estradiol secretion by porcine luteal cells is influenced by individual and combined treatment with prostaglandins E2 and F2alpha throughout the estrus cycle.
The present experiments were conducted to test whether the ratio of PGE2:PGF2alpha affects steroid secretion by porcine luteal cells. We examined the effect of separate and combined treatment with PGE2 and PGF2alpha on progesterone and estradiol secretion. Luteal cells were collected at three different stages of the luteal phase (1-3 days after ovulation; 10-12 days after ovulation and 14-16 days after ovulation). PGE2 alone in a dose dependent manner increased progesterone production by cells collected from mature corpora lutea. On the other hand, PGF2alpha in a dose dependent manner decreased progesterone secretion by cells of the same origin. Progesterone secretion by cells isolated from mature and regressing corpora lutea and treated with both prostaglandins increased in comparison to PGF2alpha-treated cultures. However, in cells collected from regressing corpora lutea PGE2 and PGF2alpha in a ratio of 2:1 and 4:1 increased estradiol production when compared to control and both ratios increased estradiol secretion in comparison to PGF2alpha-treated cells. These data 1) confirm the luteotropic effect of PGE2 and the luteolytic effect of PGF2alpha; 2) demonstrate that when the ratio of PGE2 to PGF2alpha changed from 1:1 to 2:1 or 4:1 cells were protected against the inhibitory effects of PGF2alpha on progesterone secretion by cells collected during the mid- and late luteal phase; and 3) suggest that elevated estradiol production by luteal cells, isolated during late luteal phase, under the influence of increased doses of PGE2 may serve as an additional source of estradiol to blastocysts, during early pregnancy in the pig.
Gregoraszczuk
E L
EL
Department of Animal Physiology, Institute of Zoology, Jagiellonian University, Kraków, Poland. greg@zuk.iz.uj.edu.pl
Michas
N
N
D000818:Animals; D000906:Antibodies; D002478:Cells, Cultured; D003338:Corpus Luteum / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D003429:Cross Reactions; D015237:Dinoprost / Q000494:pharmacology*; D015232:Dinoprostone / Q000494:pharmacology*; D004958:Estradiol / Q000031:analogs & derivatives / Q000276:immunology / Q000378:metabolism*; D004964:Estriol / Q000276:immunology; D004970:Estrone / Q000276:immunology; D004971:Estrus / Q000187:drug effects / Q000378:metabolism; D005260:Female; D010120:Oxytocics / Q000494:pharmacology*; D011247:Pregnancy; D011374:Progesterone / Q000378:metabolism*; D011817:Rabbits; D013552:Swine
D000906:Antibodies; D010120:Oxytocics; C026589:estradiol-6-oxime; D004970:Estrone; D011374:Progesterone; D004958:Estradiol; D015237:Dinoprost; D004964:Estriol; D015232:Dinoprostone